×ðÁú¹Ù·½

English

С¶øÃÜ´ó½ÒÃØ | sdLDL-CÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄΣº¦Òò×Ó

Ðû²¼ÓÚ£º2021-06-18

ÎÄÕÂȪԴ£º[ÖÐÎÄ]×ðÁú¹Ù·½ÉúÎï



2ÐÍÌÇÄò²¡£¡£¡£¡£ ¡£¨T2DM£©»¼ÕßÓë΢Ѫ¹ÜºÍ´óѪ¹Ü²¢·¢Ö¢Ïà¹Ø£¬ £¬£¬£¬£¬£¬£¬ÕâЩ²¢·¢Ö¢»áµ¼ÖÂÐÄÄÔѪ¹ÜÎÊÌâ[1-3]¡£¡£¡£¡£ ¡£ÓÐÑо¿Åú×¢£¬ £¬£¬£¬£¬£¬£¬ÌÇÄò²¡»¼Õß±¬·¢¹Ú×´¶¯Âö¼²²¡£¡£¡£¡£ ¡£¨CAD£©ºÍÐ£ËÀ£¨MI£©µÄΣº¦ÊÇ¿µ½¡È˵Ä2~3±¶£¬ £¬£¬£¬£¬£¬£¬84%µÄ¡Ý65ËêÌÇÄò²¡»¼ÕßËÀÓÚÐÄÔಡºÍ×äÖÐ[4]¡£¡£¡£¡£ ¡£´ó´ó¶¼2ÐÍÌÇÄò²¡»¼ÕßѪ֬´úлÒì³££¬ £¬£¬£¬£¬£¬£¬ÑªÖ¬Æ×ÌØÕ÷Ϊ֬ÖÊÈýÁªÕ÷£¬ £¬£¬£¬£¬£¬£¬¼´¸ÊÓÍÈýõ¥£¨TG£©Éý¸ß£¬ £¬£¬£¬£¬£¬£¬¸ßÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨HDL-C£©Ï½µ¡¢µÍÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨LDL-C£©Õý³£»£» £»£»£»£»£» £»òÇá¶ÈÉý¸ß£¬ £¬£¬£¬£¬£¬£¬Ð¡¶øÃܵÍÃܶÈÖ¬ÂѰף¨sdLDL£©¿ÅÁ£Ôö¶à¡£¡£¡£¡£ ¡£Ñо¿ÏÔʾ£¬ £¬£¬£¬£¬£¬£¬sdLDL-CµÄˮƽÊÇ2ÐÍÌÇÄò²¡¼°²¢·¢Ö¢µÄΣº¦Òò×Ó¡£¡£¡£¡£ ¡£


ƽ¶¥É½ÊÐÈËÃñÒ½ÔºÄÚÉøÍ¸Óë´úл¿ÆµÄÌïÓµÈÈË[5]£¬ £¬£¬£¬£¬£¬£¬ÕÐļÁ˰üÀ¨352ÃûT2DM»¼Õߣ¨ÄÐ194Ãû£¬ £¬£¬£¬£¬£¬£¬Å®158Ãû£¬ £¬£¬£¬£¬£¬£¬Æ½¾ùÄêËê60.63Ë꣩ºÍ48Ãû¿µ½¡ÈË£¨ÄÐ34Ãû£¬ £¬£¬£¬£¬£¬£¬Å®14Ãû£¬ £¬£¬£¬£¬£¬£¬Æ½¾ùÄêËê45.38Ë꣩µÄÊÜÊÔÕß¡£¡£¡£¡£ ¡£Ì½ÌÖ¶à»ùÒò¶à̬ÐÔ¡¢LDL-CºÍsdLDL-CÔÚT2DMÖÎÁÆÖеÄÁÙ´²¼ÛÖµ¡£¡£¡£¡£ ¡£Ñо¿Ê±¼ä´Ó2018Äê5ÔÂÖÁ2020Äê1Ô¡£¡£¡£¡£ ¡£Ñо¿·¢Ã÷£¬ £¬£¬£¬£¬£¬£¬sdLDL-CÖ÷Òª±£´æÓÚT2DM»¼ÕßÌåÄÚ£¬ £¬£¬£¬£¬£¬£¬ÇÒT2DM»¼ÕßsdLDL-CµÄƽ¾ùˮƽ¸ßÓÚ¿µ½¡ÈË¡£¡£¡£¡£ ¡£ÖÎÁÆºó£¬ £¬£¬£¬£¬£¬£¬LDL-CºÍsdLDL-CµÄ±í´ï½ÏÖÎÁÆÇ°½µµÍÇÒ²î±ðÏÔÖø£¨p?


352ÀýÖÎÁÆÇ°µÄT2DM»¼Õß¼°48Àý¿µ½¡ÈËLDL-CºÍsdLDL-CµÄ±í´ï


10ÀýT2DM»¼Õߣ¨ÄÐ6Àý£¬ £¬£¬£¬£¬£¬£¬Å®4Àý£©ÖÎÁÆÇ°ºó¼ì²âLDL-C£¬ £¬£¬£¬£¬£¬£¬sdLDL-CµÄˮƽ¡£¡£¡£¡£ ¡£Êý×Ö1µ½10´ú±í²¡ÈË1µ½10


ÆëÆë¹þ¶ûҽѧԺÁ¥ÊôµÚÈýÒ½ÔºµÄÑîÐã¾²µÈ[6]£¬ £¬£¬£¬£¬£¬£¬½«146ÀýT2DM»¼£¨ÆäÖÐÄÐ85Àý£¬ £¬£¬£¬£¬£¬£¬Å®61Àý£»£» £»£»£»£»£» £»ÄêËê30¡«70Ë꣩Öд¿´âT2DM»¼Õß67ÀýΪ²¡Àý×é¢ñ£¬ £¬£¬£¬£¬£¬£¬T2DM¼°²¢·¢Ö¢»¼Õß79ÀýΪ²¡Àý×é¢ò£»£» £»£»£»£»£» £»ÁíÑ¡ÔñͬÆÚ¿µ½¡Ìå¼ìÕß107Ãû×÷Ϊ±ÈÕÕ×é¡£¡£¡£¡£ ¡£Á½×é¾ù¾ÙÐÐsd LDL-C¡¢GLU¡¢TC¡¢TG¡¢LDL-C¡¢HDL-C¼ì²â¡£¡£¡£¡£ ¡£ÊÓ²ìT2DM¼°Æä²¢·¢Ö¢»¼ÕßѪÇåÖÐsdLDL-Cˮƽת±äÇéÐβ¢ÆÊÎöÆäÁÙ´²Ó¦ÓüÛÖµ¡£¡£¡£¡£ ¡£Ñо¿Ð§¹ûÅú×¢£¬ £¬£¬£¬£¬£¬£¬sd LDL-CÔÚT2DM»¼ÕßÖÐÉý¸ßÏÔ×Å£¬ £¬£¬£¬£¬£¬£¬sd LDL-CÓëTG¡¢TC¡¢LDL-C³ÊÕýÏà¹ØÓëHDL-C³Ê¸ºÏà¹Ø¡£¡£¡£¡£ ¡£ÊÓ²ìsd LDL-CµÄת±äÇéÐοÉÓÃÓÚÕ¹ÍûT2DM²¢·¢Ö¢²¡±ä±¬·¢Î£º¦¡£¡£¡£¡£ ¡£



¶«¾©´óѧ´óѧԺҽѧÑо¿ÔºÐÄѪ¹ÜÄÚ¿ÆAtsuko NakayamaµÈÈË[7]£¬ £¬£¬£¬£¬£¬£¬¶Ô¸ßµ¨¹Ì´¼ÑªÖ¢ºÏ²¢ÌÇÄò²¡ÊÓÍøÄ¤²¡±ä»¼ÕßµÄËûÍ¡ÀàÒ©ÎïÇ¿»¯ÖÎÁÆÑо¿£¨n=5042£©¾ÙÐÐÁËÆÊÎö£¬ £¬£¬£¬£¬£¬£¬¸ú×ÙÊÓ²ìÁË3.2¡À0.9Ä꣬ £¬£¬£¬£¬£¬£¬ÆÀ¹ÀÁËÖ¬ÖÊÂþÑÜÓëÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¼¤¹âÖÎÁÆÐèÇóÖ®¼äµÄÏà¹ØÐÔ¡£¡£¡£¡£ ¡£Ñо¿·¢Ã÷£¬ £¬£¬£¬£¬£¬£¬sdLDL-CµÄˮƽÓëÔØÖ¬ÂѰ×BµÄˮƽ³ÊÏÔÖøÕýÏà¹Ø£¨r=0.83£©£»£» £»£»£»£»£» £»sdLDL-CÊÇÕ¹ÍûCVÊÂÎñµÄÃô¸Ð±ê¼ÇÎp£¼0.01£©£»£» £»£»£»£»£» £»sdLDL-CÊÇÕ¹ÍûѪ֬»¼ÕßÊÇ·ñÐèÒª¼¤¹âÖÎÁƵÄÃô¸ÐÖ¸±ê£¨p=0.009£©¡£¡£¡£¡£ ¡£Ð§¹ûÅú×¢£¬ £¬£¬£¬£¬£¬£¬sdLDL-CÊÇÕ¹Íû¸ßµ¨¹Ì´¼ÑªÖ¢ºÍÌÇÄò²¡ÊÓÍøÄ¤²¡±ä»¼ÕßÐÄѪ¹ÜÊÂÎñÒÔ¼°¼¤¹âÖÎÁÆÐèÇóµÄÃô¸Ð°Ðµã±ê¼ÇÎï¡£¡£¡£¡£ ¡£


sdLDL-Cˮƽ¶ÔÐÄѪ¹ÜÊÂÎñµÄÀÛ»ýΣÏձȺÍÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¼¤¹âÖÎÁƵÄÐëÒªÐÔ



×ðÁú¹Ù·½ÉúÎïsd LDL-CÊÔ¼ÁºÐ

¹ýÑõ»¯Îïø·¨


1. Ê×¼Ò×¢²á¼°º£ÄÚÍÆ¹ã£¬ £¬£¬£¬£¬£¬£¬¿Í»§ÈϿɶȸߣ»£» £»£»£»£»£» £»

2. ¹ýÑõ»¯Îïø·¨£¬ £¬£¬£¬£¬£¬£¬Ó볬ËÙÀëÐÄ·¨ÓÐÓÅÒìµÄÏà¹ØÐÔ£¬ £¬£¬£¬£¬£¬£¬¼ì²âЧ¹û׼ȷ¡¢¿ìËÙ£»£» £»£»£»£»£» £»

3. II bÐ͸ß֬Ѫ֢¡¢MetSµÈÌØÊâÑù±¾µÄ²âÖµ¸ü׼ȷ£»£» £»£»£»£»£» £»

4. ¿¹×ÌÈÅÐÔÄÜÓÅ£¬ £¬£¬£¬£¬£¬£¬¼ì²â»ÆðãÑù±¾²»ÊÜÓ°Ï죻£» £»£»£»£»£» £»

5. »ñµÃ2016ÄêÖйúÌåÍâÕï¶ÏÊÔ¼ÁÁ¢Òì²úÆ·½±¡£¡£¡£¡£ ¡£



¡¾²Î¿¼ÎÄÏס¿

[1] Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and

risk of cause-specific death. N Engl J Med. 2011, 364(9), 829-41.

[2] American DA. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015, 33(2), 97-111.

[73] Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316(7134):823¨C8.

[4] Îâ¼Î,Íô¿¡¾ü.С¶øÃܵÍÃܶÈÖ¬ÂѰ׼ì²âÒªÁì¼°Ó¦ÓÃÏ£Íû[J].ÖлªÄ¥Á·Ò½Ñ§ÔÓÖ¾, 2017, 40(6), 417-419.

[5] Tian, Y., Wang, J., Liu, Y. et al. MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy. BMC Med Genomics 14, 83 (2021). https://doi.org/10.1186/s12920-021-00937-8.

[6] º«Ë¬, ÑîÐã¾², ÖìÔÂÆ½, µÈ. sdLDL-CÔÚT2DM¼°Æä²¢·¢Ö¢»¼ÕßÖÐѪÇåˮƽת±ä¼°ÁÙ´²Ó¦ÓÃÆÊÎö[J]. ÆëÆë¹þ¶ûҽѧԺѧ±¨, 2019, 40(9), 1080-1081.

[7] Atsuko N, Hiroyuki M, Tatsuyuki S, et al. Small Dense Low-Density Lipoprotein Cholesterol is a Potential Marker for Predicting Laser Treatment for Retinopathy in Diabetic Patients. J Atheroscler Thromb. https://doi.org/10.5551/jat.62889



END

ÎÄÕÂȪԴ£º×ðÁú¹Ù·½ÉúÎï? |? Ôð±à£ºEcho ?|? У¶Ô£ºMiss Bio¡¢Dora



 
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿